Eyebright Medical Technology (Beijing) Co., Ltd. (SHA:688050)
China
· Delayed Price · Currency is CNY 55.44
-1.52 (-2.67%)
Mar 9, 2026, 3:00 PM CST
SHA:688050 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 1,483 | 1,404 | 947.42 | 575.86 | 431.2 | Upgrade
|
| Other Revenue | - | 6.4 | 3.75 | 3.64 | 1.87 | Upgrade
|
| Revenue | 1,483 | 1,410 | 951.18 | 579.5 | 433.07 | Upgrade
|
| Revenue Growth (YoY) | 5.16% | 48.24% | 64.14% | 33.81% | 58.61% | Upgrade
|
| Cost of Revenue | - | 479.83 | 230.04 | 88.35 | 68.08 | Upgrade
|
| Gross Profit | 1,483 | 930.19 | 721.14 | 491.15 | 364.99 | Upgrade
|
| Selling, General & Admin | - | 370.67 | 296.94 | 178.57 | 142.27 | Upgrade
|
| Research & Development | - | 106.42 | 91.95 | 63.9 | 51.91 | Upgrade
|
| Other Operating Expenses | 1,193 | 4.75 | 14.98 | 8.69 | 7.17 | Upgrade
|
| Operating Expenses | 1,193 | 492.69 | 412.99 | 259.52 | 207.1 | Upgrade
|
| Operating Income | 289.94 | 437.5 | 308.16 | 231.62 | 157.89 | Upgrade
|
| Interest Expense | - | -20.73 | -9.81 | -2.02 | -0.74 | Upgrade
|
| Interest & Investment Income | - | 4.17 | 19.98 | 21.97 | 25.56 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.46 | 0.62 | -0.23 | -0.92 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.42 | -0.29 | 0.03 | -0.52 | -0.15 | Upgrade
|
| EBT Excluding Unusual Items | 289.52 | 420.19 | 318.97 | 250.81 | 181.65 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -0.69 | -1.84 | 1.49 | 0.2 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.08 | 0.11 | 0.01 | 0.02 | Upgrade
|
| Asset Writedown | - | -1.98 | - | - | - | Upgrade
|
| Other Unusual Items | - | 13.65 | 10.43 | 11.77 | 5.9 | Upgrade
|
| Pretax Income | 289.52 | 431.1 | 327.67 | 264.08 | 187.77 | Upgrade
|
| Income Tax Expense | 24.11 | 44.02 | 41.62 | 36.85 | 20.01 | Upgrade
|
| Earnings From Continuing Operations | 265.41 | 387.08 | 286.05 | 227.23 | 167.75 | Upgrade
|
| Minority Interest in Earnings | - | 1.32 | 17.93 | 5.46 | 3.59 | Upgrade
|
| Net Income | 265.41 | 388.4 | 303.98 | 232.69 | 171.34 | Upgrade
|
| Net Income to Common | 265.41 | 388.4 | 303.98 | 232.69 | 171.34 | Upgrade
|
| Net Income Growth | -31.66% | 27.77% | 30.63% | 35.80% | 77.45% | Upgrade
|
| Shares Outstanding (Basic) | 192 | 189 | 189 | 190 | 189 | Upgrade
|
| Shares Outstanding (Diluted) | 192 | 189 | 190 | 190 | 189 | Upgrade
|
| Shares Change (YoY) | 1.51% | -0.27% | 0.25% | 0.17% | 17.57% | Upgrade
|
| EPS (Basic) | 1.38 | 2.05 | 1.61 | 1.23 | 0.91 | Upgrade
|
| EPS (Diluted) | 1.38 | 2.05 | 1.60 | 1.23 | 0.91 | Upgrade
|
| EPS Growth | -32.68% | 28.13% | 30.31% | 35.58% | 50.93% | Upgrade
|
| Free Cash Flow | - | 18.27 | -157.72 | -20.9 | -91.92 | Upgrade
|
| Free Cash Flow Per Share | - | 0.10 | -0.83 | -0.11 | -0.49 | Upgrade
|
| Dividend Per Share | - | 0.350 | 0.272 | 0.283 | 0.206 | Upgrade
|
| Dividend Growth | - | 28.58% | -3.92% | 37.79% | 32.13% | Upgrade
|
| Gross Margin | 100.00% | 65.97% | 75.82% | 84.75% | 84.28% | Upgrade
|
| Operating Margin | 19.55% | 31.03% | 32.40% | 39.97% | 36.46% | Upgrade
|
| Profit Margin | 17.90% | 27.55% | 31.96% | 40.15% | 39.56% | Upgrade
|
| Free Cash Flow Margin | - | 1.30% | -16.58% | -3.61% | -21.22% | Upgrade
|
| EBITDA | 418.08 | 565.64 | 380.52 | 271.42 | 188.07 | Upgrade
|
| EBITDA Margin | 28.20% | 40.12% | 40.01% | 46.84% | 43.43% | Upgrade
|
| D&A For EBITDA | 128.14 | 128.14 | 72.36 | 39.79 | 30.18 | Upgrade
|
| EBIT | 289.94 | 437.5 | 308.16 | 231.62 | 157.89 | Upgrade
|
| EBIT Margin | 19.55% | 31.03% | 32.40% | 39.97% | 36.46% | Upgrade
|
| Effective Tax Rate | 8.33% | 10.21% | 12.70% | 13.95% | 10.66% | Upgrade
|
| Revenue as Reported | - | 1,410 | 951.18 | 579.5 | 433.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.